MRNA, the Beginning of a New Influenza Vaccine Game

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2022 Dec 5

PMID 36469761

Authors

Simone Pecetta

Rino Rappuoli

Affiliations

Soon will be listed here.

Citing Articles

[Platform technologies in vaccine development].

Hildt E Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025; .

PMID: 40035793 DOI: 10.1007/s00103-025-04024-6.

A capless hairpin-protected mRNA vaccine encoding the full-length Influenza A hemagglutinin protects mice against a lethal Influenza A infection.

Solodushko V, Kim J, Fouty B Gene Ther. 2025; .

PMID: 39988620 DOI: 10.1038/s41434-025-00521-0.

Advantages of Broad-Spectrum Influenza mRNA Vaccines and Their Impact on Pulmonary Influenza.

Cheng Z, Ma J, Zhao C Vaccines (Basel). 2025; 12(12.

PMID: 39772044 PMC: 11680418. DOI: 10.3390/vaccines12121382.

mRNA-encoded Cas13 treatment of Influenza via site-specific degradation of genomic RNA.

Chaves L, Orr-Burks N, Vanover D, Mosur V, Hosking S, Kumar E K P PLoS Pathog. 2024; 20(7):e1012345.

PMID: 38968329 PMC: 11253931. DOI: 10.1371/journal.ppat.1012345.

Frameworks for transformational breakthroughs in RNA-based medicines.

Androsavich J Nat Rev Drug Discov. 2024; 23(6):421-444.

PMID: 38740953 DOI: 10.1038/s41573-024-00943-2.

References

Ekiert D, Bhabha G, Elsliger M, Friesen R, Jongeneelen M, Throsby M . Antibody recognition of a highly conserved influenza virus epitope. Science. 2009; 324(5924):246-51. PMC: 2758658. DOI: 10.1126/science.1171491. View

Feldman R, Fuhr R, Smolenov I, Ribeiro A, Panther L, Watson M . mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019; 37(25):3326-3334. DOI: 10.1016/j.vaccine.2019.04.074. View

Sun W, He L, Zhang H, Tian X, Bai Z, Sun L . The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. Signal Transduct Target Ther. 2021; 6(1):340. PMC: 8426336. DOI: 10.1038/s41392-021-00750-w. View

Jackson M, Starita L, Kiniry E, Phillips C, Wellwood S, Cho S . Incidence of Medically Attended Acute Respiratory Illnesses Due to Respiratory Viruses Across the Life Course During the 2018/19 Influenza Season. Clin Infect Dis. 2021; 73(5):802-807. PMC: 7929037. DOI: 10.1093/cid/ciab131. View

Alameh M, Tombacz I, Bettini E, Lederer K, Sittplangkoon C, Wilmore J . Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2022; 55(6):1136-1138. PMC: 9195404. DOI: 10.1016/j.immuni.2022.05.007. View

Freyn A, Silva J, Rosado V, Bliss C, Pine M, Mui B . A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Mol Ther. 2020; 28(7):1569-1584. PMC: 7335735. DOI: 10.1016/j.ymthe.2020.04.018. View

McMahon M, ODell G, Tan J, Sarkozy A, Vadovics M, Carreno J . Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc Natl Acad Sci U S A. 2022; 119(45):e2206333119. PMC: 9659346. DOI: 10.1073/pnas.2206333119. View

Dugan H, Guthmiller J, Arevalo P, Huang M, Chen Y, Neu K . Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans. Sci Transl Med. 2020; 12(573). PMC: 8115023. DOI: 10.1126/scitranslmed.abd3601. View

Nachbagauer R, Feser J, Naficy A, Bernstein D, Guptill J, Walter E . A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2020; 27(1):106-114. DOI: 10.1038/s41591-020-1118-7. View

10.

Boyoglu-Barnum S, Ellis D, Gillespie R, Hutchinson G, Park Y, Moin S . Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature. 2021; 592(7855):623-628. PMC: 8269962. DOI: 10.1038/s41586-021-03365-x. View

11.

Rappuoli R, Dormitzer P . Influenza: options to improve pandemic preparation. Science. 2012; 336(6088):1531-3. DOI: 10.1126/science.1221466. View

12.

Dawood F, Naleway A, Flannery B, Levine M, Murthy K, Sambhara S . Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial. Clin Infect Dis. 2021; 73(11):1973-1981. PMC: 8499731. DOI: 10.1093/cid/ciab566. View

13.

Houser K, Chen G, Carter C, Crank M, Nguyen T, Burgos Florez M . Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat Med. 2022; 28(2):383-391. PMC: 10588819. DOI: 10.1038/s41591-021-01660-8. View

14.

Palese P . Influenza: old and new threats. Nat Med. 2004; 10(12 Suppl):S82-7. DOI: 10.1038/nm1141. View

15.

Wherry E, Barouch D . T cell immunity to COVID-19 vaccines. Science. 2022; 377(6608):821-822. DOI: 10.1126/science.add2897. View